COMMUNIQUÉS West-GlobeNewswire

Achieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting

10/10/2024 - 14:00

SEATTLE and VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of [...]

Konica Minolta Healthcare Partners with Clearpath Technologies to Share Medical Records and Images Digitally Through the Exa Platform

10/10/2024 - 14:00

WAYNE, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc. announces a partnership with Clearpath Technologies to integrate Clearpath’s automated platform for sharing medical records and [...]

Vireo Growth Inc. Announces Leadership Transition

10/10/2024 - 13:45

– Amber Shimpa promoted to the role of Chief Executive Officer – – Josh Rosen resigns from leadership and governance roles and retained as advisor – MINNEAPOLIS, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (" [...]

QIAGEN N.V. to release results for Q3 2024 and hold webcast

10/10/2024 - 13:41

Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024. Press release date / time: Wednesday, [...]

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

10/10/2024 - 13:30

- Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading [...]

Immatics Announces Proposed $150 Million Public Offering

10/10/2024 - 13:30

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer [...]

Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data at the American Academy of Ophthalmology 2024 Annual Meeting

10/10/2024 - 13:30

DURHAM, N.C., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced [...]

Opthea Wet AMD Program to be Presented at Innovate Retina

10/10/2024 - 13:30

MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat [...]

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

10/10/2024 - 13:30

CELEBRATION, Fla., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief [...]

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

10/10/2024 - 13:30

Q3 revenue of $22.6 million represents +8% growth year-over-year Positive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA 1 of $7.2 million Fiscal 2024 guidance revised to between $83 and $85 [...]

Theratechnologies présente de solides résultats financiers et annonce un résultat net positif pour le troisième trimestre de l’exercice 2024

10/10/2024 - 13:30

Revenus de 22,6 millions de dollars au troisième trimestre , en hausse de 8 % d’un exercice à l’autre Réalisation d’un résultat net positif de 3,1 millions de dollars, ou 0,06 $ par action, et d’un BAIIA ajusté 1 de 7,2 [...]

Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders

10/10/2024 - 13:13

Your vote is important no matter how many votes you hold. Shareholders who have questions or need assistance with voting their shares should contact info@appilitherapeutics.com HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE [...]

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

10/10/2024 - 13:01

The company is preparing for the Phase 3 study start in the first quarter of 2025 BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company [...]

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

10/10/2024 - 13:00

Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that [...]

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium

10/10/2024 - 13:00

10 October 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium LONDON, UK, [...]

RedDress Announces ActiGraft Pro Selected by Healogics for Its iSupply GPO

10/10/2024 - 13:00

TEL AVIV, Israel and JACKSONVILLE, Fla., Oct. 10, 2024 (GLOBE NEWSWIRE) -- RedDress , developers of the ActiGraft ® Pro system, a personalized and autologous wound care solution created from a patient’s own whole blood [...]

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

10/10/2024 - 13:00

Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn’s selective SMARCA2 oncology program is part of a U [...]

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

10/10/2024 - 13:00

Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes Study to support EscharEx ® BLA submission and strengthen commercialization strategy YAVNE, [...]

Tilray Brands Reports Q1 2025 Financial Results

10/10/2024 - 13:00

Tilray Achieves 13% Year-Over-Year Growth, Generating Record Q1 Net Revenue of $200 Million Q1 Gross Margin Increases Over 500 Basis Points, Representing 20% Year-Over-Year Growth Tilray Beverages Achieves 132% Net [...]